Cargando…
Pregnancy outcomes in women with pemphigus exposed to rituximab before or during pregnancy
Rituximab (RTX) is an effective treatment for pemphigus; however, the drug labeling recommends not to use RTX within 1 year before conception. OBJECTIVES: To report pregnancy outcomes of patients with pemphigus who were treated with RTX before or during pregnancy. METHODS: We identified 19 pregnanci...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276145/ https://www.ncbi.nlm.nih.gov/pubmed/35837335 http://dx.doi.org/10.1097/JW9.0000000000000038 |
_version_ | 1784745652674101248 |
---|---|
author | Dehghanimahmoudabadi, Azin Kianfar, Nika Akhdar, Marwa Dasdar, Shayan Balighi, Kamran Mahmoudi, Hamidreza Daneshpazhooh, Maryam |
author_facet | Dehghanimahmoudabadi, Azin Kianfar, Nika Akhdar, Marwa Dasdar, Shayan Balighi, Kamran Mahmoudi, Hamidreza Daneshpazhooh, Maryam |
author_sort | Dehghanimahmoudabadi, Azin |
collection | PubMed |
description | Rituximab (RTX) is an effective treatment for pemphigus; however, the drug labeling recommends not to use RTX within 1 year before conception. OBJECTIVES: To report pregnancy outcomes of patients with pemphigus who were treated with RTX before or during pregnancy. METHODS: We identified 19 pregnancies with RTX exposure before or during pregnancy. All had previously been advised not to get pregnant within 1 year of RTX administration. The cases were categorized into 3 groups of exposure of within 6 months (group A), between 6 and 12 months (group B), and longer than 12 months of conception (group C). The pregnancy outcomes of different RTX exposure intervals were compared. RESULTS: Group A included 9 pregnancies, of which 3 had received RTX accidentally after conception. Group B and C included 4 and 6 pregnancies, respectively. There was no significant difference between the groups regarding pregnancy outcomes. Overall, there were 17 live births, 1 spontaneous abortion, and 1 termination. Of the live births, 3 preterm deliveries and 4 low-birth-weight neonates were noted. Moreover, 1 neonate was hospitalized due to early-onset neonatal sepsis, and 1 had hydronephrosis. Disease flare-up occurred in 5 patients during pregnancy (4 minor and 1 major relapses) and in 5 patients after delivery (3 minor and 2 major relapses). CONCLUSIONS: Except for 1 case of neonatal sepsis which survived following medical treatment, no serious relevant adverse pregnancy outcome that could be attributed to RTX exposure before and during early pregnancy in women with pemphigus was detected. Nevertheless, RTX should not be administered within 1 year before planned pregnancy, as not enough data is available yet. |
format | Online Article Text |
id | pubmed-9276145 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-92761452022-07-13 Pregnancy outcomes in women with pemphigus exposed to rituximab before or during pregnancy Dehghanimahmoudabadi, Azin Kianfar, Nika Akhdar, Marwa Dasdar, Shayan Balighi, Kamran Mahmoudi, Hamidreza Daneshpazhooh, Maryam Int J Womens Dermatol Original Research Article Rituximab (RTX) is an effective treatment for pemphigus; however, the drug labeling recommends not to use RTX within 1 year before conception. OBJECTIVES: To report pregnancy outcomes of patients with pemphigus who were treated with RTX before or during pregnancy. METHODS: We identified 19 pregnancies with RTX exposure before or during pregnancy. All had previously been advised not to get pregnant within 1 year of RTX administration. The cases were categorized into 3 groups of exposure of within 6 months (group A), between 6 and 12 months (group B), and longer than 12 months of conception (group C). The pregnancy outcomes of different RTX exposure intervals were compared. RESULTS: Group A included 9 pregnancies, of which 3 had received RTX accidentally after conception. Group B and C included 4 and 6 pregnancies, respectively. There was no significant difference between the groups regarding pregnancy outcomes. Overall, there were 17 live births, 1 spontaneous abortion, and 1 termination. Of the live births, 3 preterm deliveries and 4 low-birth-weight neonates were noted. Moreover, 1 neonate was hospitalized due to early-onset neonatal sepsis, and 1 had hydronephrosis. Disease flare-up occurred in 5 patients during pregnancy (4 minor and 1 major relapses) and in 5 patients after delivery (3 minor and 2 major relapses). CONCLUSIONS: Except for 1 case of neonatal sepsis which survived following medical treatment, no serious relevant adverse pregnancy outcome that could be attributed to RTX exposure before and during early pregnancy in women with pemphigus was detected. Nevertheless, RTX should not be administered within 1 year before planned pregnancy, as not enough data is available yet. Lippincott Williams & Wilkins 2022-07-12 /pmc/articles/PMC9276145/ /pubmed/35837335 http://dx.doi.org/10.1097/JW9.0000000000000038 Text en Copyright © 2022 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of Women’s Dermatologic Society. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Research Article Dehghanimahmoudabadi, Azin Kianfar, Nika Akhdar, Marwa Dasdar, Shayan Balighi, Kamran Mahmoudi, Hamidreza Daneshpazhooh, Maryam Pregnancy outcomes in women with pemphigus exposed to rituximab before or during pregnancy |
title | Pregnancy outcomes in women with pemphigus exposed to rituximab before or during pregnancy |
title_full | Pregnancy outcomes in women with pemphigus exposed to rituximab before or during pregnancy |
title_fullStr | Pregnancy outcomes in women with pemphigus exposed to rituximab before or during pregnancy |
title_full_unstemmed | Pregnancy outcomes in women with pemphigus exposed to rituximab before or during pregnancy |
title_short | Pregnancy outcomes in women with pemphigus exposed to rituximab before or during pregnancy |
title_sort | pregnancy outcomes in women with pemphigus exposed to rituximab before or during pregnancy |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276145/ https://www.ncbi.nlm.nih.gov/pubmed/35837335 http://dx.doi.org/10.1097/JW9.0000000000000038 |
work_keys_str_mv | AT dehghanimahmoudabadiazin pregnancyoutcomesinwomenwithpemphigusexposedtorituximabbeforeorduringpregnancy AT kianfarnika pregnancyoutcomesinwomenwithpemphigusexposedtorituximabbeforeorduringpregnancy AT akhdarmarwa pregnancyoutcomesinwomenwithpemphigusexposedtorituximabbeforeorduringpregnancy AT dasdarshayan pregnancyoutcomesinwomenwithpemphigusexposedtorituximabbeforeorduringpregnancy AT balighikamran pregnancyoutcomesinwomenwithpemphigusexposedtorituximabbeforeorduringpregnancy AT mahmoudihamidreza pregnancyoutcomesinwomenwithpemphigusexposedtorituximabbeforeorduringpregnancy AT daneshpazhoohmaryam pregnancyoutcomesinwomenwithpemphigusexposedtorituximabbeforeorduringpregnancy |